ST8SIA1 and neoplasm: Inhibition of GD3 or its synthesizing enzyme, GD3 synthase (ST8SIA1), impairs these tumor-promoting processes, reduces tumor growth, and enhances sensitivity to temozolomide, highlighting GD3 as a compelling therapeutic target [62,63].